- Bora Pharmaceuticals is expanding its Maple Grove, Minnesota, facility with new equipment and a 100,000 sq ft buildout to support advanced oral solid dose (OSD) manufacturing.
- The expansion follows Bora’s $210 million acquisition of Upsher-Smith Laboratories in 2024 and aligns with its strategic growth in the U.S. CDMO market.
Bora Pharmaceuticals has announced a new phase of investment in its Maple Grove, Minnesota, facility to enhance manufacturing and packaging capacity for oral solid dose (OSD) products. The site, acquired in 2024 through the company’s $210 million acquisition of Upsher-Smith Laboratories, will benefit from expanded capabilities to support complex formulations and growing client demand.
As the site officially separates from Upsher-Smith on 5 August 2025, Bora is acting on increased industry reliance on contract manufacturing organisations (CDMOs) for specialised production. The company has already secured several multi-million-dollar contracts for advanced OSD development and commercial supply.
The first step of the expansion will see the installation of a Gerteis Macro-Pactor® roller compactor, expected to be operational in Q3 2025. This marks the beginning of a broader buildout of 100,000 square feet of dedicated production space at the FDA-inspected facility, which also includes quality control laboratories and a product development team.
“With pharmaceutical companies relying more heavily on specialised CDMO partners to scale production and maintain quality, top-tier manufacturing capacity and technical expertise are at a premium,” said J.D. Mowery, president of Bora’s CDMO business.
The Maple Grove site will offer integrated services across manufacturing, packaging, and analytics, supporting clients from early development through to commercial production.
